title: Amelogenin (an extracellular matrix protein) application on ischemic colon anastomosis in rats.
abstract: BACKGROUND
  Ischemia is a troublesome problem that can cause intestinal emergencies and complicate the treatment. Identification of a chemical agent with beneficial effects on the healing process in risky colon anastomosis with the aim of reducing leakage rates is a popular topic in the era of surgical research. Data is lacking about the role of amelogenin, an extracellular matrix protein, during the healing process of gastrointestinal anastomosis. In this study, the effects of amelogenin treatment on ischemic colon anastomosis were evaluated.
  
  
  METHODS
  Adult male Wistar Albino rats weighing 200-250 g were divided into three weight-matched groups as normal colon anastomosis group (n=8), ischemic colon anastomosis group (n=8), and amelogenin-treated ischemic colon anastomosis group (n=8). Sufficient equal volume of amelogenin to cover the anastomosis area entirely was applied topically. All animals were sacrificed on postoperative day four. Bursting pressure levels were measured. Peri-anastomotic colon tissue hydroxyproline levels were also assessed.
  
  
  RESULTS
  Bursting pressure level of the ischemic colon anastomosis group was significantly lower than the normal colon anastomosis and the amelogenin-treated ischemic colon anastomosis groups, respectively (p=0.006, p=0.008).
  
  
  CONCLUSIONS
  Amelogenin treatment supports the physical strength of ischemic colon anastomosis.
authors.affiliation: Department of General Surgery, İstanbul University, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey.
authors.forename: Adem
authors.initials: A
authors.lastname: Karataş
authors.forename: Ahmet
authors.initials: A
authors.lastname: Kocael
authors.forename: Erman
authors.initials: E
authors.lastname: Aytaç
authors.forename: Fahri
authors.initials: F
authors.lastname: Gökcal
authors.forename: Ziya
authors.initials: Z
authors.lastname: Salihoğlu
authors.forename: Hafize
authors.initials: H
authors.lastname: Uzun
authors.forename: Melih
authors.initials: M
authors.lastname: Paksoy
mesh_terms: D053523:Amelogenin / Q000008:administration & dosage / Q000627:therapeutic use*; D000714:Anastomosis, Surgical / Q000009:adverse effects*; D000818:Animals; D003106:Colon / Q000378:metabolism; D003108:Colonic Diseases / Q000378:metabolism / Q000601:surgery*; D016326:Extracellular Matrix Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D006909:Hydroxyproline / Q000378:metabolism; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013594:Syringes
chemical_list: D053523:Amelogenin; D016326:Extracellular Matrix Proteins; D006909:Hydroxyproline